"I think that's not good for the FDA," he says
D., Jakobsdottir, S
The position this article takes, given those three valid critiques, is that the mechanism evidence is strong enough, the delivery evidence is biologically plausible enough, and the safety window is wide enough that the recommendation is defensible
Once effective, licensed compounding pharmacies can again prepare injectable forms for prescription patients
Clinical Safety & Treatment Protocol Medical Screening: DHA-licensed physicians review medical history, cardiovascular health, medications, and treatment suitability before starting PT-141 therapy
A human RCT from Wuhan, China, showed that ALA therapy (1200 mg/d) for 7 days, could reduce a 30-day all-cause mortality rate (37.5%) in critical COVID-19 patients 535